About A public-private partnership that supports the discovery of new medicines through open access research. About SGC Partners Research Laboratories SGC-Toronto SGC-UNC SGC-Frankfurt SGC-Karolinska SGC-Neuro Governance Collaborators Open Science Equity, Diversity and Inclusion Impact Science and Resources Proteins Structure Gallery Expression Vectors Plasmids Constructs Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees ChemBioPort Chemical Probes Program CHEMICAL PROBES Donated chemical probes Chemical Handles Human Kinase Chemical Probe Program ANTIBODIES TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM Open Lab Notebooks Open Chemistry Network PUBLICATIONS People Global Aled Edwards, CEO Susan McCormick, CFO Max Morgan, General Counsel and Public Policy Director SGC Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Takis Prinos Matthieu Schapira Levon Halabelian Rachel Harding SGC UNC Tim Willson Alison Axtman David Drewry Peter J. Brown Rafael M. Couñago SGC UCL Mat Todd SGC Karolinska Michael Sundström Opher Gileadi SGC Frankfurt Stefan Knapp Susanne Müller-Knapp Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec Andreas Krämer Sandra Röhm SGC Neuro Edward Fon Thomas Durcan Jean-François Trempe Ziv Gan-Or Peter McPherson Carl Laflamme Roxanne Lariviere News & Outreach News & Events News from SGC Press Releases Events Blog Tweets by thesgconline Careers
A public-private partnership that supports the discovery of new medicines through open access research.
SGC3027 for PRMT7This probe is available from Sigma, Cayman Chemical and Tocris. The negative control (SGC3027N) is available for purchase from Sigma and Tocris. For any inquiries please contact proberequests@thesgc.org.group newOverview A collaboration between SGC, Takeda, and OICR has resulted in the discovery of SGC3027, the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is a pro-drug of SGC8158 which releases the active component upon reduction in the cell by reductases. The in vitro activity of SGC8158, the active component, includes inhibition of PRMT7 with IC50 < 2.5 nM for methylation of H2B (23-37) and greater than 40-fold selectivity over other histone methyltransferases and non-epigenetic targets. In cellular assays using C2C12 cells, SGC3027 inhibits the methylation of HSP70 with IC50 = 2.4 microM. A closely related compound, SGC3027N, is significantly less active in the cellular assay, and is an ideal control compound for cellular studies. Data relating to the discovery of this probe is being prepared for publication. In the meantime, in order to facilitate research by the community we are making this compound available through this website Properties (negative control) Physical and chemical properties for SGC3027 Molecular weight 786.3 Molecular formula C41H47ClN6O6S IUPAC name 2-(3-((4-((5-(5-amino-2,4,7,9-tetraaza-bicyclo[4.3.0]nona-1(6),2,4,7-tetraen-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl)-methylsulfanyl)-butyl)-((3-(4-chloro-phenyl)-phenyl)-methyl)-amino)-1,1-dimethyl-3-oxo-propyl)-3,5,6-trimethyl-cyclohexa-2,5-diene-1,4-dione MollogP 5.689 PSA 134.2 No. of chiral centres 4 No. of rotatable bonds 15 No. of hydrogen bond acceptors 13 No. of hydrogen bond donors 4 Physical and chemical properties for SGC3027N (Negative Control) Molecular weight 826.3 Molecular formula C44H51ClN6O6S IUPAC name 2-(3-((4-((8-(5-amino-2,4,7,9-tetraaza-bicyclo[4.3.0]nona-1(6),2,4,7-tetraen-9-yl)-3,3-dimethyl-2,4,7-trioxa-bicyclo[3.3.0]octan-6-yl)-methylsulfanyl)-butyl)-((3-(4-chloro-phenyl)-phenyl)-methyl)-amino)-1,1-dimethyl-3-oxo-propyl)-3,5,6-trimethyl-cyclohexa-2,5-diene-1,4-dione MollogP 7.431 PSA 118.9 No. of chiral centres 4 No. of rotatable bonds 15 No. of hydrogen bond acceptors 13 No. of hydrogen bond donors 2 SMILES: SGC3027: CC1=C(C)C(C(=C(C)C1=O)C(C)(C)CC(N(CCCCSC[C@@H]1[C@H]([C@H]([C@H](n2cnc3c(N)ncnc23)O1)O)O)Cc1cccc(c1)c1ccc(cc1)[Cl])=O)=O SGC3027N: CC1=C(C)C(C(=C(C)C1=O)C(C)(C)CC(N(CCCCSC[C@@H]1[C@@H]2[C@H]([C@H](n3cnc4c(N)ncnc34)O1)OC(C)(C)O2)Cc1cccc(c1)c1ccc(cc1)[Cl])=O)=O InChI: SGC3027: InChI=1S/C41H47ClN6O6S/c1-23-24(2)35(51)32(25(3)34(23)50)41(4,5)18-31(49)47(19-26-9-8-10-28(17-26)27-11-13-29(42)14-12-27)15-6-7-16-55-20-30-36(52)37(53)40(54-30)48-22-46-33-38(43)44-21-45-39(33)48/h8-14,17,21-22,30,36-37,40,52-53H,6-7,15-16,18-20H2,1-5H3,(H2,43,44,45)/t30-,36-,37-,40-/m1/s1 SGC3027N: InChI=1S/C44H51ClN6O6S/c1-25-26(2)37(54)34(27(3)36(25)53)43(4,5)20-33(52)50(21-28-11-10-12-30(19-28)29-13-15-31(45)16-14-29)17-8-9-18-58-22-32-38-39(57-44(6,7)56-38)42(55-32)51-24-49-35-40(46)47-23-48-41(35)51/h10-16,19,23-24,32,38-39,42H,8-9,17-18,20-22H2,1-7H3,(H2,46,47,48)/t32-,38-,39-,42-/m1/s1 InChIKey: SGC3027: MLJVGAYSVYMPSB-MSUKGTQXSA-N SGC3027N: FJBPSCVGHZASPG-LJVHFRCJSA-N